Immunity and Regeneration Integration Unit
Establishing cancer profiling
to develop ground-breaking, innovative, personalized medicine and therapeutics
We pursued research and development of the characteristics of “cancer stem cells” by building a drug discovery/development platform that is unparalleled in the world and based on integrated cutting-edge knowledge. By distinguishing our center’s processes from the conventional linear path from basic to clinical research, we aim to accumulate multidimensional networking information, knowledge, and applications to develop and demonstrate the highest degree of academic flexibility. We plan to contribute to the industry by building highly accurate human models that precisely reflect the response of cancer stem cells to anticancer agents such as TAS102 and patients’ pathologies, innovative cancer metabolism analysis of cancer stem cells, trans-omics analysis, and highly accurate predictive molecular markers. These plans include, but are not limited to, companion drug development, next-generation nucleic acid drug development, innovative drug delivery systems, and the redevelopment of discontinued drugs.
Department of Medical Data Science
Taiho Pharmaceutical Co., Ltd.
UNITECH Co., Ltd.
IDEA Consultants, Inc.
Department of Medical Data Science, Graduate School of Medicine, Osaka University